Dear {{Account.Salutation}} {{Account.LastName}}

 

Should you require more information, please do not hesitate to contact me.

 

Many Thanks

 

{{userName}}

{{userEmailAddress}}

{{User.MobilePhone}}

References: 1. Keating GM. Moxifloxacin 0.5% Ophthalmic Solution in Bacterial Conjunctivitis. Drugs 2011;71(1):89-99. 2. Benitez-del-Castillo J, Verboven Y, Stroman D, Kodjikian L. The Role of Topical Moxifloxacin, a New Antibacterial in Europe, in the Treatment of Bacterial Conjunctivitis. Clin Drug Investig 2011; 3(8):543-557. 3. McCulley JP. Why I Prefer Vigamox. Cataract & Refractive Surgery Today 2005;63-66. 4. Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. In Vitro and In Vivo Potency of Moxifloxacin and Moxifloxacin Ophthalmic Solution 0.5%, A New Topical Fluoroquinolone. Surv Ophthalmol 2005; 50:S16–S31. 5. VIGAMOX Eye drops, solution.  Approved professional information. 18 July 2021. 

For full prescribing information, please refer to the SAHPRA approved Professional Information  Click here to view the full VIGAMOX^® professional information

Novartis South Africa (Pty) Ltd. Magwa Crescent West, Waterfall City, Jukskei View 2090. Tel. +27 11 347 6600. Co. Reg. No. 1946/020671/07. To report Adverse Events: email: patientsafety.sacg@novartis.com • web: https://psi.novartis.com/ • Tel: 0861 929 929 • Fax: 011 929 2262. ZA2111301178  Exp. 11/2023

You are receiving this email because you have been identified as a valuable Novartis customer and we respect your privacy. For more information on how we treat your personal information, please see our privacy notice

To manage your subscription or to unsubscribe from further VIGAMOX communication please click here